Microsatellite-stable (MSS) colorectal cancer (CRC), comprising ~85–90% of cases, remains almost universally refractory to PD-1/PD-L1 monotherapy (objective response rate 5–10%), in stark contrast to the marked efficacy of immune checkpoint inhibitors (ICIs) in microsatellite-instability-high (MSI-H) disease. Here we s...
Zhi-Yuan Xia, Hai-Ning Chen, Ye-Fu Shen et al.· Frontiers in Immunology· 0 citations
The conceptual framework of metabolite-driven protein modifications is summarized, established marks are compared, and remaining questions surrounding pyruvylation chemistry, enzyme and substrate specificity, reader mechanisms, compartmentalization, detection strategies, physiological relevance, and potential immunopha...
Zi-Ye Zhang, Ming-Ze Xu, Sen Zhang et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.